Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDREW J SULICH

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1508946385
CMS profile
203983
Location
SAINT CLAIR SHORES, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$285,559.19

587 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 12 of 12; records 551–587 of 587 matching records. This page contains 37 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDREW J SULICH

NPI 1508946385 · CMS profile ID 203983

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

SAINT CLAIR SHORES, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 12 of 12; records 551–587 of 587 matching records. This page contains 37 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508946385?year=2025&recipient=provider&page=12#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDREW J SULICH, NPI 1508946385, CMS profile ID 203983. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 12 of 12; records 551–587 of 587 matching records. This page contains 37 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508946385?year=2025&recipient=provider&page=12#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ANDREW J SULICH, NPI 1508946385, CMS profile ID 203983. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 12 of 12; records 551–587 of 587 matching records. This page contains 37 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508946385?year=2025&recipient=provider&page=12#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ANDREW J SULICH, NPI 1508946385, CMS profile ID 203983, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 12 of 12; records 551–587 of 587 matching records. This page contains 37 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1508946385?year=2025&recipient=provider&page=12#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

587 matching records · $285,559.19 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 587 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 551–587 of 587.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $72.8701/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228492529 CMS
Amgen Inc. $16.2501/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228492539 CMS
Novartis Pharmaceuticals Corporation $94.1501/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200384872 CMS
SOBI, INC $17.1101/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240256717 CMS
Organon LLC $15.3901/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237725550 CMS
PFIZER INC. $2.4601/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229681270 CMS
PFIZER INC. $0.9801/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231262526 CMS
Aurinia Pharma U.S., Inc. $27.5101/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249427292 CMS
UCB, Inc. $5.7901/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224468247 CMS
ABBVIE INC. $106.8501/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204441347 CMS
ABBVIE INC. $722.2501/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1204441352 CMS
Lilly USA, LLC $17.2101/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186507843 CMS
E.R. Squibb & Sons, L.L.C. $26.0901/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184927144 CMS
E.R. Squibb & Sons, L.L.C. $0.2101/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184927146 CMS
Amgen Inc. $21.3601/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228492545 CMS
ABBVIE INC. $28.0501/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204441343 CMS
SOBI, INC $73.7801/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240256775 CMS
ANI Pharmaceuticals, Inc. $100.8001/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248583067 CMS
ANI Pharmaceuticals, Inc. $809.1601/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1248658682 CMS
UCB, Inc. $40.0001/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224468245 CMS
Amgen Inc. $5.1301/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227153643 CMS
UCB, Inc. $33.9401/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224468243 CMS
GENZYME CORPORATION $2,712.0001/10/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233285217 CMS
GENZYME CORPORATION $35.7001/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233285219 CMS
UCB, Inc. $40.0001/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224468241 CMS
Novartis Pharmaceuticals Corporation $0.8701/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200384874 CMS
Novartis Pharmaceuticals Corporation $16.6601/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200384876 CMS
GlaxoSmithKline, LLC. $0.3401/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190409139 CMS
Amgen Inc. $10.3601/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227153645 CMS
GENZYME CORPORATION $16.9701/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233285199 CMS
GlaxoSmithKline, LLC. $23.5401/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190395338 CMS
Janssen Biotech, Inc. $9.7501/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174866739 CMS
UCB, Inc. $40.8701/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224468237 CMS
UCB, Inc. $2,500.0001/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224468239 CMS
PFIZER INC. $1.0501/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231266412 CMS
PFIZER INC. $4.9501/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231322468 CMS
PFIZER INC. $13.0501/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231415042 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $407,012.04 706
PY2020 $141,289.79 330
PY2021 $227,294.44 447
PY2022 $199,128.78 536
PY2023 $231,452.55 532
PY2024 $255,723.19 580
PY2025 $285,559.19 587

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $369,270.39 23
PY2024 Principal investigator $290,101.32 14
PY2023 Principal investigator $155,418.57 10
PY2022 Recipient $51.00 1
PY2022 Principal investigator $144,163.05 5
PY2021 Recipient $434.17 2
PY2021 Principal investigator $284,035.67 27
PY2020 Recipient $302.85 1
PY2020 Principal investigator $233,071.76 52
PY2019 Recipient $84.20 1
PY2019 Principal investigator $144,228.05 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

23 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,630.30 12/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202529694
Principal investigator 1 ABBVIE INC. $680.00 12/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202526612
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $850.00 12/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289188
Principal investigator 1 Novartis Pharmaceuticals Corporation $391.45 12/01/2025 Non-covered Recipient Entity
SHORES RHEUMATOLOGY
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190302239
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $800.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289111
Principal investigator 1 ABBVIE INC. $4,080.00 11/20/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202525022
Principal investigator 1 Novartis Pharmaceuticals Corporation $17.12 11/15/2025 Non-covered Recipient Entity
SHORES RHEUMATOLOGY
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190302231
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288237
Principal investigator 1 Novartis Pharmaceuticals Corporation $144.26 06/27/2025 Non-covered Recipient Entity
SHORES RHEUMATOLOGY
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien No dispute reported 06/30/2026 1190302237
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,500.00 05/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223280404
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $300.00 05/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223279908
Principal investigator 1 ABBVIE INC. $13,000.00 05/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202483915
Principal investigator 1 UCB SA $656.83 03/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN, LLC
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246658428
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,000.00 03/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223276335
Principal investigator 1 UCB SA $84,619.00 03/06/2025 Non-covered Recipient Entity
Clinical Research Institute Of Michigan, Llc
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246659108
Principal investigator 1 Novartis Pharmaceuticals Corporation $222,337.87 03/03/2025 Non-covered Recipient Entity
SHORES RHEUMATOLOGY
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190302235
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,305.00 02/20/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN LLC
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190300599
Principal investigator 1 Novartis Pharmaceuticals Corporation $750.00 02/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN LLC
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190300597
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,500.00 02/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN LLC
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien No dispute reported 06/30/2026 1190300601
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,000.00 02/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN LLC
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190300607
Principal investigator 1 UCB SA $181.54 01/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN, LLC
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246658306
Principal investigator 1 Novartis Pharmaceuticals Corporation $85.60 01/15/2025 Non-covered Recipient Entity
SHORES RHEUMATOLOGY
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190302233
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,941.42 01/01/2025 Non-covered Recipient Entity
SHORES RHEUMATOLOGY
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190302241